ImmuPharma plc (LON:IMM – Get Free Report) shares dropped 9.4% during trading on Wednesday. The company traded as low as GBX 3.70 and last traded at GBX 3.71. 6,693,244 shares traded hands during trading, an increase of 168% from the average daily volume of 2,495,210 shares. The stock had previously closed at GBX 4.10.
ImmuPharma Price Performance
The stock has a market cap of £23.23 million, a P/E ratio of -4.48 and a beta of 3.02. The firm’s fifty day moving average price is GBX 3.64 and its two-hundred day moving average price is GBX 4.05.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. On average, research analysts expect that ImmuPharma plc will post -339.00 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
- Synchrony Aces The Quarter As Credit Fears Fade
- Higher Rates Are Sending Investors to These 3 Dividend Kings
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
